Daniel Allen Gold, Director at Roivant Sciences Ltd. (ROIV), sold 7,926,000 shares at $11.82 ($92.7M) on 2024-09-26, disclosed to the SEC on 2024-09-26.
Open-market sale of $92.7M ROIV by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $11.63 | 577,186 | $6.7M | 7.2% |
| 2 | $11.63 | 577,186 | $6.7M | 7.2% |
| 3 | $11.63 | 1,565,670 | $18.2M | 19.6% |
| 4 | $11.63 | 1,565,670 | $18.2M | 19.6% |
| 5 | $11.77 | 50,000 | $589K | 0.6% |
| 6 | $11.77 | 365,551 |
| $4.3M |
| 4.6% |
| 7 | $11.77 | 365,551 | $4.3M | 4.6% |
| 8 | $11.77 | 991,593 | $11.7M | 12.6% |
| 9 | $11.77 | 991,593 | $11.7M | 12.6% |
| 10 | $11.82 | 876,000 | $10.4M | 11.2% |
| Total | $11.70 avg | 7,926,000 | $92.7M | 100% |
| Filing → |
| ROIV | SELL | 2026-02-13 | $32.7M | — | Filing → |
| ROIV | SELL | 2025-12-18 | $71.8M | — | Filing → |
| ROIV | SELL | 2025-11-21 | $29.8M | — | Filing → |